Abortion Drug Law in Louisiana Heightens Hemorrhage Risk for Pregnant Patients

In Louisiana, a state law enacted in 2024 has raised concerns over increased hemorrhage risks for pregnant patients due to the removal of misoprostol from medical carts. The law mandates the drug's secure storage in a controlled substance room, forcing healthcare professionals to wait for it, potentially causing delays in treatment.

Misoprostol, a cheap, safe, and shelf-stable medication, was also reclassified as a controlled substance due to its use in medical abortions, which has led to its exclusion from alternative treatment options on the cart for patients with certain preexisting conditions. This reclassification has set back progress in reducing postpartum hemorrhage and blood transfusions, with Louisiana's preliminary research showing worsening hemorrhage rates statewide.

The drug is essential for reproductive healthcare, preparing cervixes for procedures, inducing labor, and managing failed pregnancies. Despite its multiple uses, Louisiana's law has sparked similar legislation in at least nine other states, though no other state has reclassified the medications. The law's impact has been met with pushback from the medical community and reproductive health advocates, who argue that it risks delaying critical medical interventions.